Persistence of HIV-1 Transmitted Drug Resistance Mutations
Open Access
- 31 July 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 208 (9), 1459-1463
- https://doi.org/10.1093/infdis/jit345
Abstract
There are few data on the persistence of individual human immunodeficiency virus type 1 (HIV-1) transmitted drug resistance (TDR) mutations in the absence of selective drug pressure. We studied 313 patients in whom TDR mutations were detected at their first resistance test and who had a subsequent test performed while ART-naive. The rate at which mutations became undetectable was estimated using exponential regression accounting for interval censoring. Most thymidine analogue mutations (TAMs) and T215 revertants (but not T215F/Y) were found to be highly stable, with NNRTI and PI mutations being relatively less persistent. Our estimates are important for informing HIV transmission models.Keywords
This publication has 20 references indexed in Scilit:
- Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecksScientific Reports, 2012
- Evolutionary pathways of transmitted drug-resistant HIV-1Journal of Antimicrobial Chemotherapy, 2011
- Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation ClassesThe Journal of Infectious Diseases, 2011
- Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settingsAIDS, 2011
- Minority Variants Associated with Transmitted and Acquired HIV-1 Nonnucleoside Reverse Transcriptase Inhibitor Resistance: Implications for the Use of Second-Generation Nonnucleoside Reverse Transcriptase InhibitorsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 UpdatePLOS ONE, 2009
- Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus InfectionJournal of Virology, 2008
- Evidence of a decline in transmitted HIV-1 drug resistance in the United KingdomAIDS, 2007
- The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational InteractionsJournal of Virology, 2007
- Persistence of HIV‐1 Variants with Multiple Protease Inhibitor (PI)–Resistance Mutations in the Absence of PI Therapy Can Be Explained by Compensatory FixationThe Journal of Infectious Diseases, 2007